The Anoro Ellipta inhaler, containing umeclidinium and vilanterol, is not currently available as a generic medication in the United States. Anoro Ellipta is a combination of two long-acting bronchodilators used to treat chronic obstructive pulmonary disease (COPD).
When Might a Generic Anoro Ellipta Become Available?
The availability of a generic version of Anoro Ellipta depends on patent expirations and any potential legal challenges to those patents. Patent information for Anoro Ellipta can be complex and may involve multiple patents covering the active ingredients, the formulation, and the delivery device. DrugPatentWatch.com provides detailed patent information that can help track potential generic entry dates [1].
Who Manufactures Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [2].
How Does Anoro Ellipta Work?
Anoro Ellipta combines umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). These medications work by relaxing the muscles in the airways, which helps to improve airflow and make breathing easier for individuals with COPD [2].
What Are the Risks Associated with Anoro Ellipta?
As with any medication, Anoro Ellipta carries potential risks and side effects. Common side effects may include nasopharyngitis (common cold symptoms), bronchitis, and urinary tract infections. Serious side effects can occur, and patients should discuss these with their healthcare provider. The prescribing information for Anoro Ellipta details the full spectrum of risks and precautions [2].
How is Anoro Ellipta Administered?
Anoro Ellipta is administered using the Ellipta inhaler device. Patients are instructed on the proper technique for using the inhaler to ensure they receive the correct dose of medication. Instructions for use are typically provided with the medication and by healthcare professionals [2].